medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2013, Number 4

<< Back Next >>

Biotecnol Apl 2013; 30 (4)

Economic-financial management modeling for biotechnology enterprises in Cuba

Castillo A, Caballero I, Triana J

Language: English
References: 22
Page: 290-298
PDF size: 235.22 Kb.


ABSTRACT

Valorization of knowledge generated by the fast advance of science and its marketing has led to the so-called “knowledge-based economy” and as a consequence high-technology (HiTech) companies have emerged. Those based in Biotechnology have some specific features compared to other HiTech sectors. This paper provides a model to structure the economic management of HiTech Biotechnology organizations in Cuba, considering the national economy and the experience accumulated by several institutions from the Scientific Biotech Pole in Western Havana. The model is based on some concepts and proposals, and it addresses key elements, such as: insurance of adequate funding levels for R&D activities and technology replacement, flexible import and export management, the ability to get into very competitive markets and preservation of a highly qualified workforce. It also demonstrates the feasibility to establish this kind of enterprises in the context and regulations already existing in a non-capitalist environment, in the middle of the update of Cuban economy.


REFERENCES

  1. Lage A. The knowledge economy and socialism: Is there an opportunity for development? Rev Cuba Socialista. 2006;41:25-43.

  2. Triana J. Looking the present, thinking on the future. In: Economy and Management: Advances in Research, Report from the Center of Studies of Cuban Economy; 2004 April, La Habana, Cuba: CEEC; 2004. p. 3-12.

  3. Di Massi JA, Grabowski HG. The cost of Biopharmaceutical R&D: Is Biotech different? Manage Decis Econ. 2007;2: 469-79.

  4. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov. 2003;2:695-702.

  5. Frazier K. Will Washington fi nd the cure for cancer. Wall Street J. 2011 Jul 13.

  6. Kureishi A. Tectonic Transformations: The Future of Biopharmaceuticals in Asia. Quintiles White Paper; 2012 [cited 2013 Aug 18]. Available from: http:// www.quintiles.com/information-library/ white-papers/

  7. Herper M. The truly staggering cost of inventing new drugs. Forbes. 2012 February 22 [cited 2013 Aug 18]. Available from: http://www.forbes.com/sites/ matthewherper/2012/02/22/the-trulystaggering- cost-ofi nventing-new-drugsthe- print-version

  8. Parkes R, Race T, Clark M. R&D productivity: Delivering suffi cient value to support post-cliff growth [Report]. Deutsche Bank AG; 2011.

  9. DiMassi JA. Risk in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69(5):297-307.

  10. Shah N. Pharmaceutical supply chains: key issues and strategies for optimization. Comp Chem Eng. 2003;28(6):929-41.

  11. Quality by design in Biomanufacturing [White paper]. Berkeley: BioG; 2011 [cited 2012 Aug 18]. Available from: http://www. BIO-G.com

  12. Hays Salary Guide 2009. Madrid: Hays Group, Spain; 2009 [cited 2013 Aug 18]. Available from: http://00rrhh.blogspot. com/2009/01/hays-presenta-la-guiasalarial- 2009.html

  13. Herrera L, Negrín S, Valdés RA. The scientifi c hub of biotechnology as a knowledge network. Rev Nueva Empresa. 2010;6(1):39-44.

  14. Langer E. Hiring in Biopharma: Where are the jobs going next? Life Sci Lead. 2012 Sept [cited 2013 Aug 18]. Available from: http://www.lifescienceleader.com

  15. Triana J. Sharing knowledge to growth: consulting and macroeconomic growth. In: Economy and Management: Advances in Research. Report from the Center of Studies of Cuban Economy (CEEC); 2004 April, La Habana, Cuba; Havana: CEEC; 2004. p. 2-22.

  16. Lage A. The Knowledge economy and Socialism: Refl ections from the experience of Cuban biotechnology. Rev Cuba Socialista. 2004;30:2-10.

  17. Lage A. Biotechnology, Science and Production: “unexplored area” of building socialism in Cuba. Marx ahora. 2009; 27:76-95.

  18. Cuba’s biotech boom [editorial]. Nature. 2009;457:130.

  19. Lage A. Biotechnology and the New Economy: Creating and valuing intangibles. Biotecnol Apl. 2000;17:55-61.

  20. Díaz I. The Cuban state enterprise: where productivity is hiding. In: Scientifi c Meeting from the Center for Studies of Cuban Economy, 2012 July, La Habana, Cuba; Havana: CEEC; 2012. p. 1-35.

  21. Consejo de Estado de la República de Cuba. Law 113 of Tax System. Gaceta Ofi cial de la República de Cuba (Edición Ordinaria). 2012;(53):1-97.

  22. Ministerio de Finanzas y Precios. Resolución No. 09/2013. Gaceta Ofi cial de la República de Cuba (Edición Extraordinaria). 2013;2:3-4.




2020     |     www.medigraphic.com